Get notified when VERA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsVera aligns with FDA on accelerated ORIGIN 3 timeline; full approval data expected Q3 2026
Filed June 2, 2026 · Period ending June 2, 2026 · ~1 min read
Key Changes
-
high
FDA agreed to earlier kidney function analysis from ORIGIN 3 trial supporting full approval of atacicept for IgA Nephropathy. Results now expected Q3 2026, ahead of prior schedule.
8-K disclosure view on EDGAR → -
high
Company plans to submit supplemental biologics license application for full approval in Q4 2026, pending positive Q3 results. Full approval would expand market access and remove post-approval study requirements.
8-K disclosure view on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FNGR 10-Q) is open in full — no account needed.
Partner
Trade VERA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify